[177Lu]Lu-PSMA-617诊疗探针用于肝细胞癌成像与治疗
[177Lu]Lu-PSMA-617与[177Lu]Lu-EB-PSMA-617在PSMA阳性肝细胞癌(HCC)皮下移植瘤小鼠模型中行单次给药放射配体治疗。SPECT/CT与生物分布显示[177Lu]Lu-EB-PSMA-617较[177Lu]Lu-PSMA-617肿瘤摄取更高、滞留更久,且血液清除更慢。37 MBq与18.5 MBq [177Lu]Lu-PSMA-617组及7.4 MBq [177Lu]Lu-EB-PSMA-617组较生理盐水组显著抑制肿瘤生长,中位生存期分别为40、44、43与30天,未见明显健康器官毒性。
要点
- 在PSMA阳性HCC移植瘤小鼠中,[177Lu]Lu-EB-PSMA-617较[177Lu]Lu-PSMA-617肿瘤摄取更高、滞留更久。
- 37 MBq与18.5 MBq [177Lu]Lu-PSMA-617组及7.4 MBq [177Lu]Lu-EB-PSMA-617组较生理盐水组显著抑制肿瘤生长。
- 各组中位生存期分别为40、44、43与30天,安全性与耐受性评价未见健康器官毒性。
核心结论
- 在PSMA阳性HCC移植瘤小鼠中,[177Lu]Lu-PSMA-617与[177Lu]Lu-EB-PSMA-617放射配体治疗显著抑制肿瘤生长并延长生存时间,未见明显毒性。
- 作者认为这些放射配体在人类临床应用方面似乎有前景,且需进一步研究。
研究设计与样本
- 研究在PSMA阳性HCC皮下移植瘤小鼠模型中探索单次给药[177Lu]Lu-PSMA-617与[177Lu]Lu-EB-PSMA-617行体内放射配体治疗的可行性。
- 制备两种药物并测定标记效率与放射化学纯度,建立HepG2人HCC皮下移植瘤小鼠模型。
- 静脉注射37 MBq [177Lu]Lu-PSMA-617或[177Lu]Lu-EB-PSMA-617后行SPECT/CT,并行生物分布研究验证靶向特异性与药代动力学。
- 放射配体治疗研究中,小鼠随机分为4组:37 MBq [177Lu]Lu-PSMA-617组、18.5 MBq [177Lu]Lu-PSMA-617组、7.4 MBq [177Lu]Lu-EB-PSMA-617组与生理盐水对照组,治疗开始时单次给药。
- 每2天监测肿瘤体积、体重与生存,治疗结束后处死小鼠,称瘤重,并通过血液检测与健康器官组织学检查评估全身毒性。
主要发现
- [177Lu]Lu-PSMA-617与[177Lu]Lu-EB-PSMA-617均成功制备,纯度高且稳定性好。
- SPECT/CT与生物分布显示,[177Lu]Lu-EB-PSMA-617较[177Lu]Lu-PSMA-617肿瘤摄取更高且滞留更久。
- [177Lu]Lu-PSMA-617自血液快速清除,而[177Lu]Lu-EB-PSMA-617在血液中滞留显著更长。
- 放射配体治疗中,37 MBq [177Lu]Lu-PSMA-617组、18.5 MBq [177Lu]Lu-PSMA-617组与7.4 MBq [177Lu]Lu-EB-PSMA-617组较生理盐水组肿瘤生长显著受抑。
- 中位生存期分别为40、44、43与30天(依次对应37 MBq [177Lu]Lu-PSMA-617组、18.5 MBq [177Lu]Lu-PSMA-617组、7.4 MBq [177Lu]Lu-EB-PSMA-617组与生理盐水组),安全性与耐受性评价未见健康器官毒性。
局限性
- 作者在结论中提出需进一步研究(future studies are warranted)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to explore the feasibility of using [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 and [177Lu]Lu-Evans blue (EB)-PSMA-617 for in vivo radioligand therapy by single-dose administration in a PSMA-positive hepatocellular carcinoma (HCC) xenograft mouse model. METHODS: [177Lu]Lu-PSMA-617 and [177Lu]Lu-EB-PSMA-617 were prepared, and labelling efficiency and radiochemical purity were determined. A HepG2 human HCC subcutaneous xenograft mouse model was established. After intravenous injection of [177Lu]Lu-PSMA-617 or [177Lu]Lu-EB-PSMA-617 (37 MBq) into the mouse model, single-photon emission computed tomography/computed tomography (SPECT/CT) was performed. Biodistribution studies were conducted to verify targeting specificity and pharmacokinetics. In the radioligand therapy study, mice were randomized into 4 groups: 37 MBq [177Lu]Lu-PSMA-617, 18.5 MBq [177Lu]Lu-PSMA-617, 7.4 MBq [177Lu]Lu-EB-PSMA-617, and saline (control). A single-dose administration was applied at the beginning of therapy studies. Tumor volume, body weight, and survival were monitored every 2 days. After the end of therapy, mice were euthanized. Tumors were then weighed, and systemic toxicity was evaluated via blood testing and histological examination of healthy organs. RESULTS: [177Lu]Lu-PSMA-617 and [177Lu]Lu-EB-PSMA-617 were successfully prepared with high purity and stability. SPECT/CT and biodistribution showed that tumor uptake was higher and persisted longer for [177Lu]Lu-EB-PSMA-617 compared with [177Lu]Lu-PSMA-617. [177Lu]Lu-PSMA-617 was rapidly cleared from the blood, while [177Lu]Lu-EB-PSMA-617 persisted for significantly longer. In radioligand therapy studies, tumor growth was significantly suppressed in the 37 MBq [177Lu]Lu-PSMA-617, 18.5 MBq [177Lu]Lu-PSMA-617, and 7.4 MBq [177Lu]Lu-EB-PSMA-617 groups compared to the saline group. Median survival was 40, 44, 43, and 30 days, respectively. No healthy organ toxicity was observed in safety and tolerability evaluation. CONCLUSIONS: Radioligand therapy using [177Lu]Lu-PSMA-617 and [177Lu]Lu-EB-PSMA-617 significantly suppressed tumor growth and prolonged survival time in PSMA-positive HCC xenograft mice without obvious toxicity. These radioligands appear promising for clinical use in humans, and future studies are warranted.
引用
- Lu Q, Long Y, Gai Y, et al. [177Lu]Lu-PSMA-617 theranostic probe for hepatocellular carcinoma imaging and therapy. Eur J Nucl Med Mol Imaging. 2023. PMID: 36877233. doi:10.1007/s00259-023-06155-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。